Over 90 Total Lots Up For Auction at One Location - WA 04/08

Siemens contemplates sale of ultrasound business

by John R. Fischer, Senior Reporter | April 13, 2021
Business Affairs Ultrasound
Siemens is considering selling its ultrasound business, which is worth about $1 billion
Siemens Healthineers is considering selling its ultrasound business, which is valued at about $1 billion.

The thought of selling came after the company received interest in the business, according to Bloomberg News.

No final decision, however, has been made on a sale at this time, and a Siemens representative declined in an email to comment on the sale to Bloomberg News. “The central aim of the Siemens Healthineers Strategy 2025 is to secure our market leadership beyond 2025.”
stats
DOTmed text ad

New Fully Configured 80-slice CT in 2 weeks with Software Upgrades for Life

For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.

stats
The company’s ultrasound business consists of devices that can be used for a range of procedures, including general scanning and advanced echocardiography. It just last year moved its ultrasound headquarters from Mountain View, California to Issaquah to finish assembling its ultra premium ACUSON Sequoia ultrasound system.

The sale would add to $161 billion worth of healthcare transactions globally this year, according to Bloomberg, which would be 260% higher than in the same period for 2020. A sale could also potentially attract private equity and strategic bidders.

The market for ultrasound, however, has declined over the last year due to a drop in routine and elective procedures brought on by the COVID-19 pandemic, reported Siemens Healthineers in its annual report.

The company recently raised $2.8 billion to fund its $16.4 billion acquisition of Varian Medical Systems — a deal that brings Siemens back into the cancer radiotherapy market since its exit in 2011. It also puts the company in a better position for joining Germany’s blue-chip DAX Index.

You Must Be Logged In To Post A Comment